| |
“Stem cell to Market faster”, by D. A. Prasanna, at ‘IsraStem 2013’, Tel Aviv 2013 |
| |
Growth in stem cell clinical research has exploded in the past decade, and so the market to supply stem cell research products has also grown to meet this demand. There are now over one million stem cell researchers worldwide. In addition, there were only 17 stem cell product companies as of 2006, and that has expanded to more than 100 today, a 6-fold increase.
The two most active areas of stem cell research are mesenchymal stem cells, at 24.8% of all stem cell research, and hematopoietic stem cells, at 24.1%. Thus, these two stem cell types account for nearly half of all stem cell research over the trailing twelve-month period. When this analysis was last conducted using data from full-year 2012 (Jan 1, 2012 – Dec 31, 2012), hematopoietic stem cell research led mesenchymal stem cell research, but that relationship has since switched.
Also of interest is that for the trailing-twelve months, induced pluripotent stem cell research activity represented 8.9% of global stem cell research activity. When this analysis was last conducted using full-year 2012 data (Jan 1, 2012 – Dec 31, 2012), induced pluripotent stem cell research activity represented only 4.0% of global research activity, which means that a substantial year-over-year shift has occurred.
This report explores why this trend has developed and how it will continue to evolve in the coming decade.
Not surprisingly, trend analysis also reveals rapid increases in overall stem cell research activity over the past five years, specifically a scientific publication rate increase of 9.9% per year. |
|
|
|
| "Biosimilar Strategy & 351K", by D. A. Prasanna, at 'CPhI 2014, Paris 2014 |
|
|
|
| “Stemcell to Market faster”, by D. A. Prasanna, at ‘IsraStem 2013’, Tel Aviv 2013 |
|
|
|
| “Cell Therapy Trials - How CROs can impact trial outcome” by Dr. S. Kher at Stemcell Symposium, Tel Aviv 2013 |
|
|
|
| “Speed to Dermatology Market and Clinical Endpoint studies“ by D.A. Prasanna & Nurjehan Jivani at BA&BE; conference, Mumbai, December 2012 |
|
|
|
| "World’s First Approved Stem Cell Drug“ – May 2012 |
|
|
|
| "Stem cell therapy clinical development capabilities“ by D A Prasanna, London, March 2010 |
|
| |
|
| |
Read this whitepaper in PDF format  |
| |
|
|
|
